ES2175834T3 - Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. - Google Patents
Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.Info
- Publication number
- ES2175834T3 ES2175834T3 ES98962480T ES98962480T ES2175834T3 ES 2175834 T3 ES2175834 T3 ES 2175834T3 ES 98962480 T ES98962480 T ES 98962480T ES 98962480 T ES98962480 T ES 98962480T ES 2175834 T3 ES2175834 T3 ES 2175834T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- haloalkyl
- radical
- hydroxyalkyl
- naphthyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto, caracterizado porque dicho compuesto es de fórmula (I), **fórmula** en la forma racémica, enantiómera o cualquier combinación de estas formas, en la cual R1 representa un radical alquilo, alquenilo, alquinilo, haloalquilo, alcoxialquilo o alquiltioalquilo; R2, R3 y R4 representan independientemente un radical H, hidroxi, alcoxi, arilalcoxi, halo, haloalquilo, alquilo, alquenilo, ciano, cianoalquilo, nitro, nitroalquilo, amido, amidoalquilo, (CH2)mNR6R7, (CH2)mOR6, (CH2)mSR6, (CH2)mCO2R6, (CH2)mNR6C(O)R8, (CH2)mC(O)R8, (CH2)mOC(O)R8, O(CH2)mNR6R7, OC(O)NR6R7, OC(O)(CH2)mCO2R6, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo, oR2 y R3, oR3 y R4, oR4 y R5, forman independientemente de forma conjunta una cadena de 3 ó 4 eslabones, en la que los elementos de la cadena se seleccionan entre el grupo constituido por CH, CH2, O,S, NoNR9; R5 representa un radical H, halo, haloalquilo, alquilo, alcoxi, alcoxialquilo, alquiltioalquilo, cicloalquilo, cicloalquilalquilo, ciano, cianoalquilo, alcanosulfonilalquilo, hidroxialquilo, nitro, (CH2)mC(O)R8, (CH2)mNR6C(O)R8, (CH2)mNR6R7, (CH2)mN(CH3)(CH2)nNR6R7, (CH2)mOC(O)R8, (CH2)mOC(O)NR6R7 o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R6 y R7 representan, independientemente, H, un radical alquilo, hidroxialquilo, alquilaminoalquilo, aminoalquilo, cicloalquilo, cicloalquilalquilo, alquenilo, alcoxialquilo, haloalquilo, uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo, o bien, cuando las cadenas R6 y R7 están unidas a un mismo átomo de nitrógeno, R6 y R7 forman eventualmente de forma conjunta un grupo morfolino, piperazino o piperidino, estando eventualmente sustituido dicho grupo con uno o varios grupos escogidos entre radicales alquilo, fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R8 representa unradical H, alquilo, hidroxialquilo, amino, alquilamino, alquilaminoalquilo, aminoalquilo, cicloalquilo, cicloalquilalquilo, alquenilo, alcoxi, alcoxialquilo, haloalquilo o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R9 representa un radical H, alquilo, haloalquilo, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos con uno de los grupos escogidos entre el radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R10 representa un radical ciano, C(O)OR11, 1H-1,2,3,4-tetrazo-5-ilo o 1-alquil-1,2,3,4-tetrazo-5-ilo; R11 representa un radical H, alquilo, haloalquilo, hidroxialquilo, alquilcarboniloxialquilo, (CH2)P NR6R7, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos en el ciclo aromático con uno o varios grupos escogidos entre el radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; m es un número entero comprendido entre 0 y 6; n es un número entero comprendido entre 1 y 4; p es un número entero comprendido entre 2 y 6; debiendo entenderse que: cada uno de los grupos alquilo que entran en las definiciones de los radicales anteriores es lineal o ramicado y comprende de 1 a 6 átomos de carbono; cada uno de los grupos alquenilo o alquinilo que entran en las definiciones de los radicales anteriores es lineal o ramificado y comprende de 2 a 6 átomos de carbono; y cada uno de los grupos cicloalquilo que entran en las definiciones de los radicales anteriores comprende de 3 a 7 átomos de carbono; o una sal farmacéuticamente aceptable de este último.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9716461A FR2772763B1 (fr) | 1997-12-24 | 1997-12-24 | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2175834T3 true ES2175834T3 (es) | 2002-11-16 |
Family
ID=9515095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98962480T Expired - Lifetime ES2175834T3 (es) | 1997-12-24 | 1998-12-16 | Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6436951B1 (es) |
| EP (1) | EP1042323B1 (es) |
| JP (1) | JP2001527075A (es) |
| AR (1) | AR016440A1 (es) |
| AT (1) | ATE215951T1 (es) |
| AU (1) | AU749224B2 (es) |
| CA (1) | CA2315897C (es) |
| DE (1) | DE69804856T2 (es) |
| DK (1) | DK1042323T3 (es) |
| ES (1) | ES2175834T3 (es) |
| FR (1) | FR2772763B1 (es) |
| HU (1) | HUP0004628A3 (es) |
| IL (1) | IL136732A0 (es) |
| MY (1) | MY117585A (es) |
| NO (1) | NO316676B1 (es) |
| NZ (1) | NZ505339A (es) |
| PL (1) | PL193468B1 (es) |
| PT (1) | PT1042323E (es) |
| RU (1) | RU2220144C2 (es) |
| TW (1) | TW513429B (es) |
| WO (1) | WO1999033829A1 (es) |
| ZA (1) | ZA9811796B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077674A1 (en) * | 2002-03-01 | 2004-04-22 | Curran Dennis P. | Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs |
| UA80552C2 (en) * | 2002-03-26 | 2007-10-10 | Combined drug of the antitumoral derivative indolopyrrolocarbazole and other antitumoral agent and its application at cancer treatment | |
| TW200623953A (en) * | 2004-12-08 | 2006-07-01 | Fuji Electric Holdings | Organic electro-luminescent element |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| JP5126707B2 (ja) * | 2007-04-23 | 2013-01-23 | 有機合成薬品工業株式会社 | α−ヒドロキシアシルピリジンの製造方法 |
| MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
| PT2430022E (pt) | 2009-05-12 | 2013-12-26 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
| US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| CN105189462B (zh) | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN103588660B (zh) * | 2013-11-18 | 2016-06-01 | 中国医学科学院生物医学工程研究所 | 一种新型的酰基苯胺化合物及用途 |
| KR101768402B1 (ko) | 2013-12-13 | 2017-08-14 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제의 억제제 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1251125B1 (fr) * | 1995-06-21 | 2005-12-07 | Société de Conseils et de Recherches d'Applications Scientifiques (S.C.R.A.S.) | Nouveaux analogues de la camptoth-cine, des proc-d-s de pr-paration, leur application comme m-dicaments et les compositions pharmaceutiques les contenant |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
-
1997
- 1997-12-24 FR FR9716461A patent/FR2772763B1/fr not_active Expired - Fee Related
-
1998
- 1998-12-14 TW TW087120746A patent/TW513429B/zh not_active IP Right Cessation
- 1998-12-15 MY MYPI98005659A patent/MY117585A/en unknown
- 1998-12-16 RU RU2000119731/04A patent/RU2220144C2/ru not_active IP Right Cessation
- 1998-12-16 DE DE69804856T patent/DE69804856T2/de not_active Expired - Lifetime
- 1998-12-16 DK DK98962480T patent/DK1042323T3/da active
- 1998-12-16 CA CA002315897A patent/CA2315897C/fr not_active Expired - Fee Related
- 1998-12-16 AU AU17645/99A patent/AU749224B2/en not_active Ceased
- 1998-12-16 PL PL98341288A patent/PL193468B1/pl not_active IP Right Cessation
- 1998-12-16 ES ES98962480T patent/ES2175834T3/es not_active Expired - Lifetime
- 1998-12-16 EP EP98962480A patent/EP1042323B1/fr not_active Expired - Lifetime
- 1998-12-16 IL IL13673298A patent/IL136732A0/xx not_active IP Right Cessation
- 1998-12-16 US US09/582,068 patent/US6436951B1/en not_active Expired - Fee Related
- 1998-12-16 WO PCT/FR1998/002751 patent/WO1999033829A1/fr active IP Right Grant
- 1998-12-16 PT PT98962480T patent/PT1042323E/pt unknown
- 1998-12-16 HU HU0004628A patent/HUP0004628A3/hu unknown
- 1998-12-16 JP JP2000526510A patent/JP2001527075A/ja not_active Ceased
- 1998-12-16 NZ NZ505339A patent/NZ505339A/xx active IP Right Revival
- 1998-12-16 AT AT98962480T patent/ATE215951T1/de not_active IP Right Cessation
- 1998-12-21 AR ARP980106556A patent/AR016440A1/es unknown
- 1998-12-22 ZA ZA9811796A patent/ZA9811796B/xx unknown
-
2000
- 2000-06-23 NO NO20003314A patent/NO316676B1/no not_active IP Right Cessation
- 2000-12-12 US US09/734,167 patent/US6632946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL193468B1 (pl) | 2007-02-28 |
| FR2772763B1 (fr) | 2004-01-23 |
| NO316676B1 (no) | 2004-03-29 |
| WO1999033829A1 (fr) | 1999-07-08 |
| HUP0004628A1 (hu) | 2001-05-28 |
| EP1042323A1 (fr) | 2000-10-11 |
| RU2220144C2 (ru) | 2003-12-27 |
| US6632946B2 (en) | 2003-10-14 |
| NO20003314L (no) | 2000-06-30 |
| MY117585A (en) | 2004-07-31 |
| IL136732A0 (en) | 2001-06-14 |
| PT1042323E (pt) | 2002-09-30 |
| FR2772763A1 (fr) | 1999-06-25 |
| DK1042323T3 (da) | 2002-08-05 |
| TW513429B (en) | 2002-12-11 |
| DE69804856T2 (de) | 2002-11-07 |
| JP2001527075A (ja) | 2001-12-25 |
| ATE215951T1 (de) | 2002-04-15 |
| NO20003314D0 (no) | 2000-06-23 |
| EP1042323B1 (fr) | 2002-04-10 |
| AU749224B2 (en) | 2002-06-20 |
| US6436951B1 (en) | 2002-08-20 |
| AU1764599A (en) | 1999-07-19 |
| US20010000521A1 (en) | 2001-04-26 |
| AR016440A1 (es) | 2001-07-04 |
| ZA9811796B (en) | 1999-06-29 |
| NZ505339A (en) | 2003-01-31 |
| HUP0004628A3 (en) | 2001-11-28 |
| DE69804856D1 (de) | 2002-05-16 |
| CA2315897C (fr) | 2010-01-19 |
| CA2315897A1 (fr) | 1999-07-08 |
| PL341288A1 (en) | 2001-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2175834T3 (es) | Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. | |
| ATE44383T1 (de) | Bisacylphosphinoxide, ihre herstellung und verwendung. | |
| AR013494A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| AR004195A1 (es) | Nuevos derivados de la 5-0 desosaminil-6-0-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios, metodo de aplicacionde los mismos para la preparacion de productos biologicamente activos. | |
| ES2199696B1 (es) | Mezclas de estabilizantes. | |
| DK1204662T3 (da) | Azaindoler med serotoninreceptoraffinitet | |
| HUP0004588A2 (hu) | Szubsztituált 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-ol-származékok, eljárás előállításukra és alkalmazásuk gyógyszerként, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| ES8601897A1 (es) | Un metodo de preparar derivados de 4-quinolona | |
| DK0664287T3 (da) | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse | |
| DE69416683T2 (de) | Benzolactam-derivate | |
| CO5011097A1 (es) | Derivados de 8-azabiciclo [3.2.1]octan-3-metanamina . | |
| EA200300458A1 (ru) | Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их | |
| ZA851127B (en) | New 3-phenyl-2-propeneamine derivatives,their preparation and compositions containing them | |
| ES8702380A1 (es) | Procedimiento para preparar un derivado de (imina ciclica)- difenil-eter | |
| ATE27811T1 (de) | Ester von 2-adamantanonoxim. | |
| BG102429A (en) | Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means | |
| ES2115855T3 (es) | Nuevos derivados de 17-iminometilalquenil-5-beta-14-beta-androstanos y 17-iminoalquil-5-beta,14-beta-androstanos, un procedimiento para su produccion y las composiciones farmaceuticas que los incluyen. | |
| MX9304249A (es) | Derivados de n-acildihidroquinolina, metodo para su produccion y composiciones herbicidas que los contienen. | |
| CO4940468A1 (es) | Nuevos derivados de naftilpiperacina | |
| ATE136036T1 (de) | Androst-4-en(4,5-b>-pyrrol-derivate und ein verfahren zu ihrer herstellung | |
| TW349935B (en) | Oxime ether compounds, their intermediates and their use as pesticides | |
| TH892EX (th) | อนุพันธ์ไทรฟลูออโรมีเธนซัลโฟนานิลีดและการใช้ประโยชน์ | |
| DE3361834D1 (en) | Dithiino (1,4) (2,3-c) pyrrole derivatives, their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1042323 Country of ref document: ES |